Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit
June 15, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the...
Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips
June 06, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With...
Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results
May 15, 2023 16:05 ET
|
Absci Corporation
Commenced work plan preparations and expect to initiate program work during second quarter leveraging Absci's generative AI drug creation platform for Phase II candidate Achieved rapid advancements...
University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies
May 11, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and OXFORD, UK, May 11, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and the University of Oxford’s Kennedy Institute of...
Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 06, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, April 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the...
Absci Partners with Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology
April 04, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and TAMPA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and M2GEN, an oncology bioinformatics company with the...
Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
March 30, 2023 16:05 ET
|
Absci Corporation
Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI 10 new Active Programs in 2022, exceeding full-year...
Absci to Participate in the B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation
March 23, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually...
Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
March 07, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually...
Absci Expands in Europe with Launch of New Innovation Center and Additional Senior Leadership in Switzerland
February 28, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced its expansion into the European...